Please login to the form below

Not currently logged in
Email:
Password:

umeclidinium

This page shows the latest umeclidinium news and features for those working in and with pharma, biotech and healthcare.

AZ’s COPD triple data sets up market clash with GSK

AZ’s COPD triple data sets up market clash with GSK

on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year.

Latest news

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    Nucala itself saw sales more than double to £91m, but the approval of new triple therapy Trelegy (fluticasone furoate/umeclidinium/vilanterol) - billed as another key growth driver - came too late in

  • With US approval, GSK now needs rapid uptake for COPD triple With US approval, GSK now needs rapid uptake for COPD triple

    The FDA approved Trelegy (fluticasone furoate/umeclidinium/vilanterol) for the long-term, once-daily maintenance treatment of COPD patients who suffer breakthrough exacerbations despite being treated with two-drug combinations. ... for those on triple

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The EMA's advisory committee gave its blessing for Trelegy/Elebrato (fluticasone furoate, umeclidinium and vilanterol) as a maintenance therapy for COPD patients who do not respond to two-drug therapy ... The new product adds long-acting muscarinic

  • GSK preps COPD filing for asthma pioneer Nucala GSK preps COPD filing for asthma pioneer Nucala

    agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium – and shingles vaccine Shingrix which is up for an FDA advisory committee meeting later today.

More from news
Approximately 9 fully matching, plus 48 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics